• Home
  • News
  • Coins2Day 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
NewslettersBrainstorm Health

Juul’s CEO Steps Down. But What Comes Next?: Brainstorm Health

By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
September 25, 2019, 8:13 PM ET

Hello and happy hump day, readers.

Perhaps it was inevitable in the face of lawsuits, regulatory crackdowns, reports of horrifying lung illnesses, and a general sense of unease—but Kevin Burns, CEO of the privately-held firm Juul, is stepping down from his perch.

The Juul CEO’s sudden departure is just one chapter in this rapidly unfolding story. Here’s another excerpt: The tobacco giant Altria, which bought a 35% stake in Juul last year at a reported $40 billion valuation, is no longer in talks with Philip Morris International (PMI) to bring the companies together again.

Altria spun off PMI more than a decade ago while holding on to the U.S.-based Philip Morris unit (which controls major brands such as Marlboro in America). PMI has been focused on “heat not burn” tobacco products in international markets (these are not the same things as vapes). The divergent business strategies, and the public health outcry against vaping and e-cigs, almost certainly sunk any potential deal.

But what happens next? Will PMI’s bet on heat-not-burn devices actually pay dividends in the consumer market? And, more importantly, are these devices any better from a public health perspective than the vaping products facing blowback right now?

Read on for the day’s news.

Sy Mukherjee, @the_sy_guy, [email protected]

DIGITAL HEALTH

Amazon is launching an employee health clinic. CNBC's Chrissy Farr (who else?) Reports on Amazon's latest foray into health care, dubbed, well, Amazon Care. Farr describes it as a "virtual primary care" for employees that offers a combination of telemedicine and in-person services. (CNBC)

INDICATIONS

The flip side of the cancer drug boom. It's hard to argue that creating more cancer drugs is a bad thing. But almost everything in business and drug development comes with the possibility of adverse events—including opportunity cost. BioPharma Dive reports on the struggles of cancer drug centers to keep up with the clinical demand in an illuminating piece. (BioPharma Dive)

REQUIRED READING

How the Impeachment Process Could Affect the Stock Market, by Erik Sherman

Facebook's Big Hopes in Augmented and Virtual Reality Face Even Bigger Obstacles, by Danielle Abril

The World's Forests Are Burning—And the Damage Goes Far Beyond the Amazon, by Nicolas Rapp & Brian O'Keefe

Find past coverage. Sign up for other Coins2Day newsletters.

About the Author
By Sy Mukherjee
See full bioRight Arrow Button Icon
Rankings
  • 100 Best Companies
  • Coins2Day 500
  • Global 500
  • Coins2Day 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Coins2Day Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Coins2Day Brand Studio
  • Coins2Day Analytics
  • Coins2Day Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Coins2Day
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Coins2Day Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Coins2Day Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.